Biosimilars-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Biosimilars-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Biosimilars industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Biosimilars 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Biosimilars worldwide and market share by regions, with company and product introduction, position in the Biosimilars market
Market status and development trend of Biosimilars by types and applications
Cost and profit status of Biosimilars, and marketing status
Market growth drivers and challenges
The report segments the global Biosimilars market as:
Global Biosimilars Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Biosimilars Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody
Hormone
Growth Factors
Global Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Global Biosimilars Market: Manufacturers Segment Analysis (Company and Product introduction, Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Biosimilars-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Biosimilars industry, standing on the readers’ perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Biosimilars 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Biosimilars worldwide and market share by regions, with company and product introduction, position in the Biosimilars market
Market status and development trend of Biosimilars by types and applications
Cost and profit status of Biosimilars, and marketing status
Market growth drivers and challenges
The report segments the global Biosimilars market as:
Global Biosimilars Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Biosimilars Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Antibody
Hormone
Growth Factors
Global Biosimilars Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
Global Biosimilars Market: Manufacturers Segment Analysis (Company and Product introduction, Biosimilars Sales Volume, Revenue, Price and Gross Margin):
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
United Laboratories
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF BIOSIMILARS
1.1 Definition of Biosimilars in This Report
1.2 Commercial Types of Biosimilars
1.2.1 Antibody
1.2.2 Hormone
1.2.3 Growth Factors
1.3 Downstream Application of Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biosimilars
1.5 Market Status and Trend of Biosimilars 2013-2023
1.5.1 Global Biosimilars Market Status and Trend 2013-2023
1.5.2 Regional Biosimilars Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Biosimilars 2013-2017
2.2 Sales Market of Biosimilars by Regions
2.2.1 Sales Volume of Biosimilars by Regions
2.2.2 Sales Value of Biosimilars by Regions
2.3 Production Market of Biosimilars by Regions
2.4 Global Market Forecast of Biosimilars 2018-2023
2.4.1 Global Market Forecast of Biosimilars 2018-2023
2.4.2 Market Forecast of Biosimilars by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Biosimilars by Types
3.2 Sales Value of Biosimilars by Types
3.3 Market Forecast of Biosimilars by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Biosimilars by Downstream Industry
4.2 Global Market Forecast of Biosimilars by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Biosimilars Market Status by Countries
5.1.1 North America Biosimilars Sales by Countries (2013-2017)
5.1.2 North America Biosimilars Revenue by Countries (2013-2017)
5.1.3 United States Biosimilars Market Status (2013-2017)
5.1.4 Canada Biosimilars Market Status (2013-2017)
5.1.5 Mexico Biosimilars Market Status (2013-2017)
5.2 North America Biosimilars Market Status by Manufacturers
5.3 North America Biosimilars Market Status by Type (2013-2017)
5.3.1 North America Biosimilars Sales by Type (2013-2017)
5.3.2 North America Biosimilars Revenue by Type (2013-2017)
5.4 North America Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Biosimilars Market Status by Countries
6.1.1 Europe Biosimilars Sales by Countries (2013-2017)
6.1.2 Europe Biosimilars Revenue by Countries (2013-2017)
6.1.3 Germany Biosimilars Market Status (2013-2017)
6.1.4 UK Biosimilars Market Status (2013-2017)
6.1.5 France Biosimilars Market Status (2013-2017)
6.1.6 Italy Biosimilars Market Status (2013-2017)
6.1.7 Russia Biosimilars Market Status (2013-2017)
6.1.8 Spain Biosimilars Market Status (2013-2017)
6.1.9 Benelux Biosimilars Market Status (2013-2017)
6.2 Europe Biosimilars Market Status by Manufacturers
6.3 Europe Biosimilars Market Status by Type (2013-2017)
6.3.1 Europe Biosimilars Sales by Type (2013-2017)
6.3.2 Europe Biosimilars Revenue by Type (2013-2017)
6.4 Europe Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Biosimilars Market Status by Countries
7.1.1 Asia Pacific Biosimilars Sales by Countries (2013-2017)
7.1.2 Asia Pacific Biosimilars Revenue by Countries (2013-2017)
7.1.3 China Biosimilars Market Status (2013-2017)
7.1.4 Japan Biosimilars Market Status (2013-2017)
7.1.5 India Biosimilars Market Status (2013-2017)
7.1.6 Southeast Asia Biosimilars Market Status (2013-2017)
7.1.7 Australia Biosimilars Market Status (2013-2017)
7.2 Asia Pacific Biosimilars Market Status by Manufacturers
7.3 Asia Pacific Biosimilars Market Status by Type (2013-2017)
7.3.1 Asia Pacific Biosimilars Sales by Type (2013-2017)
7.3.2 Asia Pacific Biosimilars Revenue by Type (2013-2017)
7.4 Asia Pacific Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Biosimilars Market Status by Countries
8.1.1 Latin America Biosimilars Sales by Countries (2013-2017)
8.1.2 Latin America Biosimilars Revenue by Countries (2013-2017)
8.1.3 Brazil Biosimilars Market Status (2013-2017)
8.1.4 Argentina Biosimilars Market Status (2013-2017)
8.1.5 Colombia Biosimilars Market Status (2013-2017)
8.2 Latin America Biosimilars Market Status by Manufacturers
8.3 Latin America Biosimilars Market Status by Type (2013-2017)
8.3.1 Latin America Biosimilars Sales by Type (2013-2017)
8.3.2 Latin America Biosimilars Revenue by Type (2013-2017)
8.4 Latin America Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Biosimilars Market Status by Countries
9.1.1 Middle East and Africa Biosimilars Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Biosimilars Revenue by Countries (2013-2017)
9.1.3 Middle East Biosimilars Market Status (2013-2017)
9.1.4 Africa Biosimilars Market Status (2013-2017)
9.2 Middle East and Africa Biosimilars Market Status by Manufacturers
9.3 Middle East and Africa Biosimilars Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Biosimilars Sales by Type (2013-2017)
9.3.2 Middle East and Africa Biosimilars Revenue by Type (2013-2017)
9.4 Middle East and Africa Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILARS
10.1 Global Economy Situation and Trend Overview
10.2 Biosimilars Downstream Industry Situation and Trend Overview
CHAPTER 11 BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Biosimilars by Major Manufacturers
11.2 Production Value of Biosimilars by Major Manufacturers
11.3 Basic Information of Biosimilars by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Biosimilars Major Manufacturer
11.3.2 Employees and Revenue Level of Biosimilars Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Roche
12.1.1 Company profile
12.1.2 Representative Biosimilars Product
12.1.3 Biosimilars Sales, Revenue, Price and Gross Margin of Roche
12.2 Amgen
12.2.1 Company profile
12.2.2 Representative Biosimilars Product
12.2.3 Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
12.3 AbbVie
12.3.1 Company profile
12.3.2 Representative Biosimilars Product
12.3.3 Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
12.4 Sanofi-Aventis
12.4.1 Company profile
12.4.2 Representative Biosimilars Product
12.4.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
12.5 Johnson & Johnson
12.5.1 Company profile
12.5.2 Representative Biosimilars Product
12.5.3 Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.6 Pfizer
12.6.1 Company profile
12.6.2 Representative Biosimilars Product
12.6.3 Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
12.7 Novo Nordisk
12.7.1 Company profile
12.7.2 Representative Biosimilars Product
12.7.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.8 Eli Lilly
12.8.1 Company profile
12.8.2 Representative Biosimilars Product
12.8.3 Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
12.9 Novartis
12.9.1 Company profile
12.9.2 Representative Biosimilars Product
12.9.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
12.10 Merck
12.10.1 Company profile
12.10.2 Representative Biosimilars Product
12.10.3 Biosimilars Sales, Revenue, Price and Gross Margin of Merck
12.11 Sun
12.11.1 Company profile
12.11.2 Representative Biosimilars Product
12.11.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sun
12.12 3sbio
12.12.1 Company profile
12.12.2 Representative Biosimilars Product
12.12.3 Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
12.13 Changchun High Tech
12.13.1 Company profile
12.13.2 Representative Biosimilars Product
12.13.3 Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech
12.14 CP Guojian
12.14.1 Company profile
12.14.2 Representative Biosimilars Product
12.14.3 Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian
12.15 Biotech
12.15.1 Company profile
12.15.2 Representative Biosimilars Product
12.15.3 Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
12.16 Gelgen
12.17 Innovent
12.18 Dong Bao
12.19 Ganlee
12.20 United Laboratories
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILARS
13.1 Industry Chain of Biosimilars
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILARS
14.1 Cost Structure Analysis of Biosimilars
14.2 Raw Materials Cost Analysis of Biosimilars
14.3 Labor Cost Analysis of Biosimilars
14.4 Manufacturing Expenses Analysis of Biosimilars
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Biosimilars in This Report
1.2 Commercial Types of Biosimilars
1.2.1 Antibody
1.2.2 Hormone
1.2.3 Growth Factors
1.3 Downstream Application of Biosimilars
1.3.1 Tumor
1.3.2 Diabetes
1.3.3 Cardiovascular
1.3.4 Hemophilia
1.3.5 Other
1.4 Development History of Biosimilars
1.5 Market Status and Trend of Biosimilars 2013-2023
1.5.1 Global Biosimilars Market Status and Trend 2013-2023
1.5.2 Regional Biosimilars Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Biosimilars 2013-2017
2.2 Sales Market of Biosimilars by Regions
2.2.1 Sales Volume of Biosimilars by Regions
2.2.2 Sales Value of Biosimilars by Regions
2.3 Production Market of Biosimilars by Regions
2.4 Global Market Forecast of Biosimilars 2018-2023
2.4.1 Global Market Forecast of Biosimilars 2018-2023
2.4.2 Market Forecast of Biosimilars by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Biosimilars by Types
3.2 Sales Value of Biosimilars by Types
3.3 Market Forecast of Biosimilars by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Biosimilars by Downstream Industry
4.2 Global Market Forecast of Biosimilars by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Biosimilars Market Status by Countries
5.1.1 North America Biosimilars Sales by Countries (2013-2017)
5.1.2 North America Biosimilars Revenue by Countries (2013-2017)
5.1.3 United States Biosimilars Market Status (2013-2017)
5.1.4 Canada Biosimilars Market Status (2013-2017)
5.1.5 Mexico Biosimilars Market Status (2013-2017)
5.2 North America Biosimilars Market Status by Manufacturers
5.3 North America Biosimilars Market Status by Type (2013-2017)
5.3.1 North America Biosimilars Sales by Type (2013-2017)
5.3.2 North America Biosimilars Revenue by Type (2013-2017)
5.4 North America Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Biosimilars Market Status by Countries
6.1.1 Europe Biosimilars Sales by Countries (2013-2017)
6.1.2 Europe Biosimilars Revenue by Countries (2013-2017)
6.1.3 Germany Biosimilars Market Status (2013-2017)
6.1.4 UK Biosimilars Market Status (2013-2017)
6.1.5 France Biosimilars Market Status (2013-2017)
6.1.6 Italy Biosimilars Market Status (2013-2017)
6.1.7 Russia Biosimilars Market Status (2013-2017)
6.1.8 Spain Biosimilars Market Status (2013-2017)
6.1.9 Benelux Biosimilars Market Status (2013-2017)
6.2 Europe Biosimilars Market Status by Manufacturers
6.3 Europe Biosimilars Market Status by Type (2013-2017)
6.3.1 Europe Biosimilars Sales by Type (2013-2017)
6.3.2 Europe Biosimilars Revenue by Type (2013-2017)
6.4 Europe Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Biosimilars Market Status by Countries
7.1.1 Asia Pacific Biosimilars Sales by Countries (2013-2017)
7.1.2 Asia Pacific Biosimilars Revenue by Countries (2013-2017)
7.1.3 China Biosimilars Market Status (2013-2017)
7.1.4 Japan Biosimilars Market Status (2013-2017)
7.1.5 India Biosimilars Market Status (2013-2017)
7.1.6 Southeast Asia Biosimilars Market Status (2013-2017)
7.1.7 Australia Biosimilars Market Status (2013-2017)
7.2 Asia Pacific Biosimilars Market Status by Manufacturers
7.3 Asia Pacific Biosimilars Market Status by Type (2013-2017)
7.3.1 Asia Pacific Biosimilars Sales by Type (2013-2017)
7.3.2 Asia Pacific Biosimilars Revenue by Type (2013-2017)
7.4 Asia Pacific Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Biosimilars Market Status by Countries
8.1.1 Latin America Biosimilars Sales by Countries (2013-2017)
8.1.2 Latin America Biosimilars Revenue by Countries (2013-2017)
8.1.3 Brazil Biosimilars Market Status (2013-2017)
8.1.4 Argentina Biosimilars Market Status (2013-2017)
8.1.5 Colombia Biosimilars Market Status (2013-2017)
8.2 Latin America Biosimilars Market Status by Manufacturers
8.3 Latin America Biosimilars Market Status by Type (2013-2017)
8.3.1 Latin America Biosimilars Sales by Type (2013-2017)
8.3.2 Latin America Biosimilars Revenue by Type (2013-2017)
8.4 Latin America Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Biosimilars Market Status by Countries
9.1.1 Middle East and Africa Biosimilars Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Biosimilars Revenue by Countries (2013-2017)
9.1.3 Middle East Biosimilars Market Status (2013-2017)
9.1.4 Africa Biosimilars Market Status (2013-2017)
9.2 Middle East and Africa Biosimilars Market Status by Manufacturers
9.3 Middle East and Africa Biosimilars Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Biosimilars Sales by Type (2013-2017)
9.3.2 Middle East and Africa Biosimilars Revenue by Type (2013-2017)
9.4 Middle East and Africa Biosimilars Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF BIOSIMILARS
10.1 Global Economy Situation and Trend Overview
10.2 Biosimilars Downstream Industry Situation and Trend Overview
CHAPTER 11 BIOSIMILARS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Biosimilars by Major Manufacturers
11.2 Production Value of Biosimilars by Major Manufacturers
11.3 Basic Information of Biosimilars by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Biosimilars Major Manufacturer
11.3.2 Employees and Revenue Level of Biosimilars Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 BIOSIMILARS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Roche
12.1.1 Company profile
12.1.2 Representative Biosimilars Product
12.1.3 Biosimilars Sales, Revenue, Price and Gross Margin of Roche
12.2 Amgen
12.2.1 Company profile
12.2.2 Representative Biosimilars Product
12.2.3 Biosimilars Sales, Revenue, Price and Gross Margin of Amgen
12.3 AbbVie
12.3.1 Company profile
12.3.2 Representative Biosimilars Product
12.3.3 Biosimilars Sales, Revenue, Price and Gross Margin of AbbVie
12.4 Sanofi-Aventis
12.4.1 Company profile
12.4.2 Representative Biosimilars Product
12.4.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sanofi-Aventis
12.5 Johnson & Johnson
12.5.1 Company profile
12.5.2 Representative Biosimilars Product
12.5.3 Biosimilars Sales, Revenue, Price and Gross Margin of Johnson & Johnson
12.6 Pfizer
12.6.1 Company profile
12.6.2 Representative Biosimilars Product
12.6.3 Biosimilars Sales, Revenue, Price and Gross Margin of Pfizer
12.7 Novo Nordisk
12.7.1 Company profile
12.7.2 Representative Biosimilars Product
12.7.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.8 Eli Lilly
12.8.1 Company profile
12.8.2 Representative Biosimilars Product
12.8.3 Biosimilars Sales, Revenue, Price and Gross Margin of Eli Lilly
12.9 Novartis
12.9.1 Company profile
12.9.2 Representative Biosimilars Product
12.9.3 Biosimilars Sales, Revenue, Price and Gross Margin of Novartis
12.10 Merck
12.10.1 Company profile
12.10.2 Representative Biosimilars Product
12.10.3 Biosimilars Sales, Revenue, Price and Gross Margin of Merck
12.11 Sun
12.11.1 Company profile
12.11.2 Representative Biosimilars Product
12.11.3 Biosimilars Sales, Revenue, Price and Gross Margin of Sun
12.12 3sbio
12.12.1 Company profile
12.12.2 Representative Biosimilars Product
12.12.3 Biosimilars Sales, Revenue, Price and Gross Margin of 3sbio
12.13 Changchun High Tech
12.13.1 Company profile
12.13.2 Representative Biosimilars Product
12.13.3 Biosimilars Sales, Revenue, Price and Gross Margin of Changchun High Tech
12.14 CP Guojian
12.14.1 Company profile
12.14.2 Representative Biosimilars Product
12.14.3 Biosimilars Sales, Revenue, Price and Gross Margin of CP Guojian
12.15 Biotech
12.15.1 Company profile
12.15.2 Representative Biosimilars Product
12.15.3 Biosimilars Sales, Revenue, Price and Gross Margin of Biotech
12.16 Gelgen
12.17 Innovent
12.18 Dong Bao
12.19 Ganlee
12.20 United Laboratories
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF BIOSIMILARS
13.1 Industry Chain of Biosimilars
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF BIOSIMILARS
14.1 Cost Structure Analysis of Biosimilars
14.2 Raw Materials Cost Analysis of Biosimilars
14.3 Labor Cost Analysis of Biosimilars
14.4 Manufacturing Expenses Analysis of Biosimilars
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
